Daclatasvir and reduced-dose sofosbuvir: an effective and pangenotypic treatment for hepatitis C in patients with eGFR <30 ml/min.
about
Daclatasvir and reduced-dose sofosbuvir: an effective and pangenotypic treatment for hepatitis C in patients with eGFR <30 ml/min.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Daclatasvir and reduced-dose s ...... patients with eGFR <30 ml/min.
@en
Daclatasvir and reduced-dose s ...... patients with eGFR <30 ml/min.
@nl
type
label
Daclatasvir and reduced-dose s ...... patients with eGFR <30 ml/min.
@en
Daclatasvir and reduced-dose s ...... patients with eGFR <30 ml/min.
@nl
prefLabel
Daclatasvir and reduced-dose s ...... patients with eGFR <30 ml/min.
@en
Daclatasvir and reduced-dose s ...... patients with eGFR <30 ml/min.
@nl
P2093
P50
P356
P1433
P1476
Daclatasvir and reduced-dose s ...... patients with eGFR <30 ml/min.
@en
P2093
Amit Gupta
Anupma Kaul
Dharmendra S Bhadauria
Mayank Mehrotra
Praveer Rai
Raj K Sharma
P304
P356
10.1111/NEP.13222
P577
2018-01-12T00:00:00Z